---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-107753"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:32:39.031646+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Protagonist Q3 net loss $39.3M (-$0.62); cash $678.8M; icotrokinra filed, rusfertide NDA expected Q4

## Summary
- Net loss of $39.3M ($0.62 diluted EPS loss) vs $33.2M loss in Q3 2024.
- Cash $678.8M, up from $559.2M at year-end 2024; provides runway through at least end 2028.
- Icotrokinra NDA submitted to FDA (July) and EMA (September) for moderate-to-severe plaque psoriasis.
- Rusfertide granted FDA Breakthrough Therapy designation; Phase 3 VERIFY 52-week data at ASH Dec 2025; NDA filing expected Q4 2025.
- First patient dosed in Phase 1 for oral IL-17 antagonist PN-881.

## SEC filing metadata
- accession: 0001104659-25-107753
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465925107753/0001104659-25-107753-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465925107753/tm2530353d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-107753
- JSON: https://secwatch.observer/filing/0001104659-25-107753.json
- Plain text: https://secwatch.observer/filing/0001104659-25-107753.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.